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Abstract
Noonan syndrome is a relatively common
and heterogeneous genetic disorder, associat-
ed with congenital heart defect in about 50% of
the cases. If the defect is not severe, life
expectancy is normal. We report a case of
Noonan syndrome in a preterm infant with
hypertrophic cardiomyopathy and lethal out-
come associated to acute respiratory distress
syndrome caused by Adenovirus pneumonia. A
novel mutation in the RAF1 gene was identi-
fied: c.782C>G (p.Pro261Arg) in heterozygosi-
ty, not described previously in the literature.
Consequently, the common clinical course in
this mutation and its respective contribution
to the early fatal outcome is unknown. No con-
clusion can be established regarding geno-
type/phenotype correlation.
Introduction
Hypertrophic cardiomyopathy (HCM) is
defined by the presence of increased left ven-
tricular wall thickness that is not solely
explained by abnormal loading conditions.
This definition applies to children and adults
and makes no a priori assumptions about eti-
ology or myocardial pathology.1 In newborns,
HCM may be associated with prenatal tran-
sient causes including maternal diabetes, fetal
hypoxia with impaired intrauterine growth
and administration of corticosteroids. It can
also occur as a secondary effect to polymalfor-
mative syndromes such as Noonan, LEOPARD,
Beckwith-Weidemann, or Barth,  inborn errors
of metabolism like deposit diseases
(glycogenosis, mucopolysaccharidosis, oligo -
saccharidosis, sphingolipidosis), disorders of
energy metabolism (fatty acid oxidation
defects and carnitine deficiency) and neuro-
muscular syndromes (Friedrich ataxia and
Duchenne muscular dystrophy).2,3 The current
case describes a preterm with Noonan syn-
drome due to a novel RAF1 mutation, who
developed a rapidly progressive hypertrophic
cardiomyopathy with fatal outcome, in the con-
text of cardiorespiratory failure associated
with Adenovirus pneumonia.
Case Report
This male infant was born to healthy non-
consanguineous parents. It was the mother’s
first pregnancy, complicated at 28 weeks of
gestation by polyhydramnios. The fetal ultra-
sounds revealed bilateral hydronephrosis
(right 14 mm, left 10 mm), bladder wall thick-
ening and shortened long bones. He was deliv-
ered at the 30th week of gestation by cesarean
section due to fetal distress by placental abrup-
tion. Apgar scores were 3/3/4 at one, five and
ten minutes respectively, with sustained
bradycardia. The bodyweight was 1840 g (P75-
90), height 38 cm (P10) and head circumfer-
ence 32 cm (P90). The newborn was intubated
and ventilated in the first minutes and one
dose of exogenous surfactant was given due to
respiratory distress syndrome. Physical exami-
nation revealed marked hypotonia, generalized
edema and shortened limbs. The echocardio-
gram showed poor contractility, low cardiac
output, myocardial hypertrophy and mild peri-
cardial effusion. Hence, the newborn was sub-
mitted to invasive ventilation, fluid replace-
ment, albumin and inotropic support. He devel-
oped metabolic acidosis requiring correction
and antibiotic therapy was performed due to
sepsis. In the first days of life, cerebral ultra-
sound was normal. In the second day, a weight
loss of 7.6% was confirmed, along with redun-
dant skin, course facies, hepatomegaly and
palpable kidneys. The echocardiogram showed
improved function and vascular filling, left
myocardial hypertrophy and signs of pul-
monary hypertension. Clinical and electric
seizures were observed, requiring treatment
with phenobarbital. On day four, dopamine was
suspended but invasive ventilation and dobut-
amine were maintained. Five days later venti-
latory and hemodynamic status were stable on
non-invasive ventilation. At this time a signif-
icant reduction of edema (weight loss of 400 g:
−22% of weight birth) was observed. On day
ten, dobutamine was suspended and the
echocardiogram confirmed hypertrophic car-
diomyopathy with left ventricular outflow tract
obstruction (Figure 1). Propranolol was initiat-
ed (maximum dose of 4 mg/kg/day) with the
heart rate around 150 bpm. Seizures were con-
trolled and cerebral ultrasound on day 15
revealed a grade II intraperiventricular hemor-
rhage. Investigation included karyotype
(46,XY), plasma amino acids, serum lactate,
ammonia, total and esterified carnitine, urine
metabolic screen and renal ultrasound, all with
normal results. TORCH screen was negative.
A molecular study for RASopathies, testing
for specific mutations in PTPN11, BRAF, SOS1,
HRAS, KRAS, RAF1, MAP2K1, and MAP2K2,
revealed a novel RAF1 gene mutation:
c.782C>G (p.Pro261Arg) in heterozygosity,
forecasting a diagnosis of probable Noonan
syndrome. The genetic parents’ study was neg-
ative. On day 31, a cerebral magnetic reso-
nance showed intraventricular and parenchy-
mal venous infarction and relatively poor gyra-
tion, with the presence of shallow grooves
especially in the frontal regions (Figure 2).
There was some decrease of the left ventric-
ular outflow tract obstruction, under high pro-
pranolol doses and the newborn remained clin-
ically stable in dependence on noninvasive
ventilation and oxygen therapy. On day 60
(postmenstrual age 39th+4 weeks), he devel-
oped respiratory failure requiring invasive
ventilation and antibiotics due to pneumonia.
Adenovirus was isolated in respiratory secre-
tions. It progressed to Acute Respiratory
Distress Syndrome, requiring high-frequency
ventilation and pulmonary vasodilators (nitric
oxide and sildenafil) for refractory hypoxemia.
On day 79, severe pulmonary hypertension and
congestive heart failure with low cardiac out-
put were registered. Despite the therapeutic
optimization, cardiorespiratory status wors-
ened and he died in the 80th day.
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Discussion
The RASopathies are a clinically defined
group of medical genetic syndromes caused by
germline mutations in genes that encode com-
ponents or regulators of the RAS/mitogen-acti-
vated protein kinase (MAPK) pathway. These
disorders include neurofibromatosis type 1,
Noonan syndrome, LEOPARD syndrome, capil-
lary malformation-arteriovenous malformation
syndrome, Costello syndrome, cardio-facio-
cutaneous syndrome, and Legius syndrome.
Given the common underlying RAS/MAPK
pathway dysregulation, the RASopathies
exhibit numerous overlapping phenotypic fea-
tures.4-6
The combination of prenatal features like
polyhydramnios, hydrops, shortened long
bones and somatic characteristics such as
excessive neck skin, widely spaced nipples and
low-set ears is suggestive of Noonan syn-
drome. In the present case, the diagnosis of
Noonan syndrome was made based on HCM
associated with clinical characteristics and
normal karyotype.7
Noonan syndrome is a relatively common
genetic condition with an incidence of one in
1,000 to 2,000 live births.6,7 Mutations have
been described in 7 genes: PTPN11 (50%),
SOS1 (20%), RAF1 (15%), KRAS (5%), and
NRAS, BRAF, MAP2K1 (in fewer than 2%),
causing gain-of-function and up-regulation of
the RAS-MAPK pathway. The condition is often
inherited as an autosomal dominant trait, but
at least 50% of these mutations occur de novo,
as observed in this patient.1,6,8 In the current
case, we identified a novel mutation in the
RAF1 gene (c.782C>G (p.Pro261Arg) in het-
erozygosity. Two different mutations have
been described in this position,
c.782C>A(p.Pro261His) and c.782C>T
(p.Pro261Leu), and three additional ones also
affecting the same residue, c.781C>T
(p.Pro261Ser), c.781C>G(p.Pro261Ala) and
c.781C>A(p.Pro261Thr). There is a submis-
sion of this variant in ClinVar.9 It was classi-
fied by the submitting user as an uncertain
significance germline variant, but it was not
provided the status (affected/unaffected) of
that individual. It is in dbSNP (rs397516828)
as a not validated entry.
Bioinformatic software analysis with Align
GVGD (class C65), MutationTaster (disease
causing), SIFT (deleterious) and PolyPhen-2
(probably damaging), were consistent predict-
ing that the variant found is most likely patho-
genic. Additionally, the mutation was not pres-
ent in both unaffected parents, and, therefore,
is most likely de novo. This, along with the pre-
sented data, indicates that this variant is very
likely pathogenic and the cause of Noonan syn-
drome in this patient.
The syndrome is associated with a wide
variety of signs and symptoms due to multi-
organ involvement. It is a very heterogeneous
disorder, predominantly characterized by dys-
morphic facial features, post-natal short
stature, webbed neck, chest deformity, cryp-
torchidism in men, lymphatic dysplasia, vari-
able bleeding disorders, and intellectual dis-
ability.2,6,10
Rare structural cerebral anomalies are
described and we speculate if the cerebral
alterations found in this case were related to
the pathology. 
Noonan syndrome is also linked to congeni-
tal cardiac defects, with an estimated rate of
35-50%. The predominant lesions are pul-
monary valve stenosis and HCM, followed by
atrial and ventricular septal defects. HCM is
present in about 20% of NS patients and in
95% of mutations in the RAF1 gene.2,10
The HCM in our patient was not detected on
prenatal ultrasound but rather in the first days
of life. The natural course of HCM is markedly
variable. While some patients may become
symptomatic and succumb in early childhood,
others may remain asymptomatic until late
childhood. Rapidly progressive HCM, resulting
in an early death or a need for heart transplan-
tation, occurs only sporadically in Noonan
Syndrome and other RASopathies.2,7 Hirsch et
al reported two children with Noonan syn-
drome and hypertrophic cardiomyopathy who
developed progressive left ventricular outflow
tract obstruction over the first year of life.11
They died at 9 and 23 months of age, respec-
tively. In our patient, HCM conducted to car-
diorespiratory failure but prematurity and res-
piratory infection have also contributed to the
early death. However, since the common clini-
cal course in this mutation is unknown, it is
impossible to assess its contribution to the
early fatal outcome.  
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